Surmodics | SRDX - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
Abbott USD 68M 26M 2026-03
Align Technology USD 16.04M 14.04M 2025-12
Anika Therapeutics 179.39M 556.84M 2026-03
Arrowhead Research USD 22.5M 811K 2025-12
Artivion USD 5.53M 589K 2025-12
Baxter International USD 58M 14M 2025-09
Boston Scientific USD 90M 0 2026-03
EDAP TMS EUR 49K 8K 2025-09
Edwards Lifesciences USD 35.9M 2.7M 2025-12
Haemonetics USD 7.21M 3.14M 2025-09
Heron Therapeutics USD 600K 100K 2024-12
J&J USD 43M 25M 2026-03
Merit Medical Systems USD 6.53M 162K 2026-03
Mesa Laboratories USD 3.02M 180K 2024-09
Nektar Therapeutics USD 9.77M 3.75M 2025-12
Option Care Health USD 13.3M 570K 2026-03
Stryker USD 607M 450M 2025-12
Surmodics USD 884K 5K 2024-09
Trinity Biotech USD 3.33M 50K 2025-09